Rituximab biosimilar - Biocad

Drug Profile

Rituximab biosimilar - Biocad

Alternative Names: AcellBia; Acellbia; BCD-020; USMAL

Latest Information Update: 06 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocad
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Preregistration Rheumatoid arthritis

Most Recent Events

  • 13 Jun 2018 Safety and efficacy data from the phase III ALTERRA trial in Rheumatoid arthritis presented at the 19th Annual Congress of the European League Against Rheumatism(EULAR-2018)
  • 29 Nov 2017 Biocad announces intention to launch Rituximab biosimilar in Morocco, Senegal, Gabon and Côte d’Ivoire
  • 01 Aug 2017 Biocad completes a phase III trial in Rheumatoid arthritis (Treatment-naive, Combination therapy) in Russia (IV) (NCT02744196)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top